PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model

Leukemia

Volumn 29, Issue 6, 2015, Pages 1350-1359

  Motiwala, T ^a,d   Kutay, H ^a   Zanesi, N ^a   Frissora, F W ^b   Mo, X ^a   Muthusamy, N ^c   Jacob, S T ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d Tzagournis Medical Research Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROTEIN P53; TRANSCRIPTION FACTOR FOXM1; TRUNCATED PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE O; TUMOR MARKER; UNCLASSIFIED DRUG; BCR PROTEIN, MOUSE; BREAKPOINT CLUSTER REGION PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, MOUSE; MESSENGER RNA; ONCOPROTEIN; PTPRO PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; TCL1A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CANCER SURVIVAL; CELL SPECIFICITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; TRANSCRIPTION INITIATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DNA MICROARRAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; B-LYMPHOCYTES; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFLAMMATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930572910     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.341     Document Type: Article

References (35)

1. Wiggins RC, Wiggins JE, Goyal M, Wharram BL, Thomas PE. Molecular cloning of cDNAs encoding human GLEPP1, a membrane protein tyrosine phosphatase: characterization of the GLEPP1 protein distribution in human kidney and assignment of the GLEPP1 gene to human chromosome 12p12-p13. Genomics 1995; 27: 174-181.
2. Wharram BL, Goyal M, Gillespie PJ, Wiggins JE, Kershaw DB, Holzman LB et al. Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000; 106: 1281-1290.
3. Beltran PJ, Bixby JL, Masters BA. Expression of PTPRO during mouse development suggests involvement in axonogenesis and differentiation of NT-3 and NGF-dependent neurons. J Comp Neurol 2003; 456: 384-395.
4. Aguiar RC, Yakushijin Y, Kharbanda S, Tiwari S, Freeman GJ, Shipp MA. PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood 1999; 94: 2403-2413.
5. Hsu SH, Motiwala T, Roy S, Claus R, Mustafa M, Plass C et al. Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate. J Cell Biochem 2013; 114: 1810-1818.
6. Ramaswamy B, Majumder S, Roy S, Ghoshal K, Kutay H, Datta J et al. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol Endocrinol 2009; 23: 176-187.
7. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 2007; 13: 3174-3181.
8. Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci USA 2004; 101: 13844-13849.
9. Motiwala T, Ghoshal K, Das A, Majumder S, Weichenhan D, Wu YZ et al. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 2003; 22: 6319-6331.
10. Jacob ST, Motiwala T. Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther 2005; 12: 665-672.
11. Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S et al. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells. J Biol Chem 2009; 284: 455-464.
12. Shintani T, Ihara M, Sakuta H, Takahashi H, Watakabe I, Noda M. Eph receptors are negatively controlled by protein tyrosine phosphatase receptor type O. Nat Neurosci 2006; 9: 761-769.
13. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 2006; 108: 3428-3433.
14. Motiwala T, Datta J, Kutay H, Roy S, Jacob ST. Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib. J Cell Biochem 2010; 110: 846-856.
15. Huang YT, Li FF, Ke C, Li Z, Li ZT, Zou XF et al. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J Transl Med 2013; 11: 245.
16. You YJ, Chen YP, Zheng XX, Meltzer SJ, Zhang H. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett 2012; 315: 138-144.
17. American Cancer Society: Cancer Facts and Figures. American Cancer Society, 2012. Available at http://www.cancer.org/research/cancerfactsstatistics/.
18. Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM et al. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 2011; 118: 6132-6140.
19. Pekarsky Y, Zanesi N, Croce CM. Molecular basis of CLL. Semin Cancer Biol 2010; 20: 370-376.
20. Zanesi N, Balatti V, Bottoni A, Croce CM, Pekarsky Y. Novel insights in molecular mechanisms of CLL. Curr Pharm Des 2012; 18: 3363-3372.
21. Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 2006; 20: 280-285.
22. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006; 66: 915-920.
23. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-6960.
24. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
25. Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol 2010; 6: 377.
26. Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, Lee J et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469-4476.
27. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113: 3050-3058.
28. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011; 117: 1662-1669.
29. Barsotti AM, Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 2009; 28: 4295-4305.
30. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 2011; 10: 1046-1058.
31. Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 2010; 16: 528-536.
32. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177: 1821-1826.
33. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011; 117: 5463-5472.
34. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F et al. Loss of p53 and altered miR15-a/16-1short right arrowMCL-1 pathway in CLL: insights from TCL1-Tg:p53 (? / ) mouse model and primary human leukemia cells. Leukemia 2014; 28: 118-128.
35. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-3329.